Metazero Xr

Metoprolol succinate, the active ingredient in Metazero Xr, is a beta blocker presented as an oral tablet for oral use. It treats hypertension, chronic stable angina, heart failure, and post‑myocardial infarction in adult patients.

GNH USA supplies Metazero Xr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metazero Xr, a beta‑adrenergic blocker, is used in several cardiovascular conditions.

Hypertension: lowers blood pressure by reducing heart rate and contractility. Chronic stable angina: decreases myocardial oxygen demand to relieve chest pain. Heart failure: improves survival and reduces hospitalizations by moderating cardiac workload. Post‑myocardial infarction: helps prevent recurrent cardiac events by stabilising heart rhythm and pressure.

Metazero Xr may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Fatigue or tiredness. - Dizziness or light‑headedness. - Bradycardia (slow heart rate). - Cold extremities or hands and feet. - Gastrointestinal upset such as nausea. - Sleep disturbances or vivid dreams.

Serious or Rare Side Effects: - Severe bradycardia or heart block. - Marked hypotension. - Bronchospasm, especially in patients with asthma. - Allergic reactions including rash or angioedema. - Depression or mood changes. - Worsening heart failure symptoms.

Before prescribing Metazero Xr, clinicians should consider several safety measures.

Monitor blood pressure: check regularly to ensure therapeutic control. Assess heart rate: watch for bradycardia, especially in patients with conduction disorders. Evaluate renal function: dose adjustment may be needed in impairment. Review concomitant beta‑blockers: avoid duplicate therapy. Store at ambient temperature: keep below 25°C, protect from moisture.

Metazero Xr can interact with various medicines, requiring careful management.

Major Interactions (Avoid): - Concomitant non‑selective beta‑blockers: risk of excessive cardiac depression. - Calcium channel blockers (verapamil, diltiazem): may cause severe bradycardia. - Antidiabetic agents: can mask hypoglycaemia symptoms. - MAO inhibitors: potential for hypertensive crisis. - Certain antidepressants (e.g., SSRIs): may increase bradycardia risk.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: additive hypotensive effect. - Diuretics: may enhance blood‑pressure lowering. - NSAIDs: can reduce antihypertensive efficacy. - Antithyroid drugs: may affect heart rate control. - Antimicrobials (e.g., erythromycin): may increase plasma levels of metoprolol.